• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Hypothyroidism as a late sequela in patient with Graves' disease treated with antithyroid agents.甲状腺功能减退症作为接受抗甲状腺药物治疗的格雷夫斯病患者的晚期后遗症。
J Clin Invest. 1979 Nov;64(5):1429-36. doi: 10.1172/JCI109601.
2
Clinical experience with sensitive thyrotropin measurements: diagnostic and therapeutic implications.敏感促甲状腺激素测量的临床经验:诊断和治疗意义
J Nucl Med. 1985 Nov;26(11):1248-56.
3
Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT).胺碘酮所致甲状腺毒症(AIT)患者的放射性碘治疗。
Neuro Endocrinol Lett. 2009;30(2):209-14.
4
[Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].[采用简化剂量测定法进行放射性碘治疗甲状腺功能亢进症。临床结果]
Radiol Med. 2000 Dec;100(6):480-3.
5
Comparison between TRH-stimulated TSH and basal TSH measurement by a commercial immunoradiometric assay in the management of thyroid disease.在甲状腺疾病管理中,通过一种商业免疫放射分析方法对促甲状腺激素释放激素(TRH)刺激后的促甲状腺激素(TSH)与基础TSH测量结果的比较。
Q J Nucl Med. 1996 Jun;40(2):182-7.
6
Three patients who spontaneously developed persistent hypothyroidism during or following treatment with antithyroid drugs for Graves' hyperthyroidism.三名在使用抗甲状腺药物治疗格雷夫斯甲亢期间或之后自发出现持续性甲状腺功能减退的患者。
Arch Intern Med. 1990 May;150(5):1105-9.
7
Thyroid function and histology in forty-five patients with hyperthyroid Graves' disease in clinical remission more than ten years after thionamide drug treatment.硫酰胺类药物治疗后临床缓解超过十年的45例甲状腺功能亢进型格雷夫斯病患者的甲状腺功能和组织学
J Clin Endocrinol Metab. 1986 Jan;62(1):165-9. doi: 10.1210/jcem-62-1-165.
8
Pituitary-thyroid regulation in euthyroid patients with Graves' disease previously treated with antithyroid drugs.既往接受抗甲状腺药物治疗的格雷夫斯病甲状腺功能正常患者的垂体-甲状腺调节。
J Clin Endocrinol Metab. 1976 Aug;43(2):419-27. doi: 10.1210/jcem-43-2-419.
9
Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.慢性碘给药对既往因格雷夫斯甲亢接受抗甲状腺药物治疗的甲状腺功能正常受试者甲状腺状态的影响。
J Clin Endocrinol Metab. 1993 Apr;76(4):928-32. doi: 10.1210/jcem.76.4.7682562.
10
Laboratory tests for evaluating thyroid therapy.评估甲状腺治疗的实验室检查。
Am Fam Physician. 1982 Sep;26(3):183-8.

引用本文的文献

1
Oscillation between Hyperthyroidism and Hypothyroidism in an Adolescent Female with Graves' Disease.一名患有格雷夫斯病的青春期女性甲状腺功能亢进与甲状腺功能减退的交替发作
J ASEAN Fed Endocr Soc. 2025 May;40(1):117-120. doi: 10.15605/jafes.040.01.07. Epub 2025 Apr 25.
2
A 2023 International Survey of Clinical Practice Patterns in the Management of Graves Disease: A Decade of Change.2023 年全球 Graves 病管理临床实践模式调查:十年变迁。
J Clin Endocrinol Metab. 2024 Oct 15;109(11):2956-2966. doi: 10.1210/clinem/dgae222.
3
Long-Term Outcome of Graves' Disease: A Gender Perspective.格雷夫斯病的长期转归:性别视角
Womens Health Rep (New Rochelle). 2023 Oct 9;4(1):487-496. doi: 10.1089/whr.2023.0073. eCollection 2023.
4
A case of Hashimoto's thyroiditis following Graves' disease.1例格雷夫斯病后发生的桥本甲状腺炎。
Clin Case Rep. 2022 Oct 13;10(10):e6466. doi: 10.1002/ccr3.6466. eCollection 2022 Oct.
5
2022 European Thyroid Association Guideline for the management of pediatric Graves' disease.2022年欧洲甲状腺协会儿童格雷夫斯病管理指南
Eur Thyroid J. 2022 Jan 1;11(1):e210073. doi: 10.1530/ETJ-21-0073.
6
Cellular and molecular basis of thyroid autoimmunity.甲状腺自身免疫的细胞和分子基础。
Eur Thyroid J. 2022 Jan 1;11(1):e210024. doi: 10.1530/ETJ-21-0024.
7
How to use thionamide anti-thyroid drug in the young- what's new?如何在年轻人中使用硫酰胺类抗甲状腺药物——有哪些新进展?
Thyroid Res. 2021 Jul 21;14(1):18. doi: 10.1186/s13044-021-00109-x.
8
DES-Tcell is a knowledgebase for exploring immunology-related literature.DES-T 细胞是一个用于探索免疫学相关文献的知识库。
Sci Rep. 2021 Jul 12;11(1):14344. doi: 10.1038/s41598-021-93809-1.
9
Basedow's disease with associated features of Hashimoto's thyroiditis based on histopathological findings.基于组织病理学发现的伴有桥本甲状腺炎相关特征的 Basedow 病。
BMC Endocr Disord. 2020 Aug 5;20(1):120. doi: 10.1186/s12902-020-00602-8.
10
Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis.阿仑单抗诱导的多发性硬化症甲状腺事件:系统评价和荟萃分析。
J Endocrinol Invest. 2020 Feb;43(2):219-229. doi: 10.1007/s40618-019-01105-7. Epub 2019 Aug 26.

本文引用的文献

1
STANDARDIZATION OF TSH TESTING.促甲状腺激素检测的标准化
J Clin Endocrinol Metab. 1965 Feb;25:266-77. doi: 10.1210/jcem-25-2-266.
2
RISING INCIDENCE OF HYPOTHYROIDISM AFTER RADIOACTIVE-IODINE THERAPY IN THYROTOXICOSIS.甲状腺毒症放射性碘治疗后甲状腺功能减退症发病率上升
N Engl J Med. 1964 Nov 12;271:1037-42. doi: 10.1056/NEJM196411122712004.
3
Twelve years' experience of antithyroid treatment.十二年抗甲状腺治疗经验。
Postgrad Med J. 1962 May;38(439):275-80. doi: 10.1136/pgmj.38.439.275.
4
Nonsurgical treatment of thyrotoxicosis.甲状腺毒症的非手术治疗。
Proc R Soc Med. 1961 Oct;54:869-71.
5
Electrocardiographic changes following the administration of thyroid stimulating hormone (thyrotropin).注射促甲状腺激素(促甲状腺素)后的心电图变化。
Am J Cardiol. 1960 Nov;6:905-14. doi: 10.1016/0002-9149(60)90290-3.
6
Physiological responses of five middle-aged and elderly men to repeated administration of thyroid stimulating hormone (thyrotropin; TSH).五名中老年男性对重复注射促甲状腺激素(促甲状腺素;TSH)的生理反应。
J Gerontol. 1959 Jan;14(1):37-47. doi: 10.1093/geronj/14.1.37.
7
A test of thyroid and pituitary function using thyrotrophin.一项使用促甲状腺激素的甲状腺和垂体功能测试。
Clin Sci. 1958 Feb;17(1):113-20.
8
The significance of low thyroid reserve.低甲状腺储备的意义。
J Clin Endocrinol Metab. 1956 Nov;16(11):1438-55. doi: 10.1210/jcem-16-11-1438.
9
Long-term therapy of thyrotoxicosis with thiouracil compounds.用硫脲类化合物对甲状腺毒症进行长期治疗。
Br Med J. 1954 Feb 20;1(4859):422-5. doi: 10.1136/bmj.1.4859.422.
10
Propylthiouracil: 4-6 year follow-up of selected patients with Graves' disease.丙硫氧嘧啶:对部分格雷夫斯病患者进行的4至6年随访
J Clin Endocrinol Metab. 1953 Dec;13(12):1507-12. doi: 10.1210/jcem-13-12-1507.

甲状腺功能减退症作为接受抗甲状腺药物治疗的格雷夫斯病患者的晚期后遗症。

Hypothyroidism as a late sequela in patient with Graves' disease treated with antithyroid agents.

作者信息

Wood L C, Ingbar S H

出版信息

J Clin Invest. 1979 Nov;64(5):1429-36. doi: 10.1172/JCI109601.

DOI:10.1172/JCI109601
PMID:91625
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC371292/
Abstract

In 1971, thyroid function was evaluated in 15 unselected patients whose only therapy for diffuse toxic goiter was a course of thionamide drug treatment completed 20-27 yr earlier. One patient was frankly hypothyroid by clinical and laboratory criteria. The remaining 14 patients appeared clinically euthyroid and had a normal serum thyroxine (T(4)) concentration and thyroid radioiodine uptake (RAIU). Nevertheless, only 6 of 14 appeared to be entirely normal according to more refined criteria. The serum thyrotropin (TSH) concentration was markedly elevated in one patient and above the normal range (1.6+/-2.0; mean+/-2 SD) in five others. Thyroid stimulation with exogenous TSH revealed subnormal responses of the serum T(4)I, RAIU, or both, in 7 of 11 patients tested. An abnormal iodideperchlorate discharge test was found in 5 of 10 patients and appeared most abnormal in patients with abnormal RAIU responses to TSH. Fluorescent antimicrosomal antibody was found in the serum of 12 of the 15 patients, in contrast to an expected frequency of 7% in normal individuals of the same age. By the time a second major follow-up study was completed in 1978, two additional patients had become frankly hypothyroid. A third subject met accepted criteria for subclinical hypothyroidism. One of these subjects had had a clearly elevated serum TSH concentration in 1972, and the remaining two had exhibited the highest responses of serum TSH (36, 26 muU/ml) to thyrotropin-releasing hormone among 10 patients tested in 1972. One patient developed recurrent thyrotoxicosis in 1978, 25 yr after the onset of his first and only other apparent episode of hyperthyroidism. This patient was the only one who demonstrated a subnormal response to thyrotropin-releasing hormone in 1972. The remaining nine subjects that could be studied in 1978 exhibited varying combinations of abnormalities of thyroid function. It is concluded that progressive failure of thyroid function is a common occurence in long-standing Graves' disease, and it is suggested that this results from concomitant chronic thyroiditis. We postulate that this inherent tendency toward thyroid failure is exaggerated by surgery or radioactive iodine, explaining the progressive increase in, and inordinate frequency of, hypothyroidism after ablative modes of therapy in diffuse toxic goiter.

摘要

1971年,对15例未经挑选的患者进行了甲状腺功能评估,这些患者唯一接受过的弥漫性毒性甲状腺肿治疗是在20至27年前完成的一个硫酰胺类药物疗程。根据临床和实验室标准,1例患者明显甲状腺功能减退。其余14例患者临床甲状腺功能正常,血清甲状腺素(T4)浓度和甲状腺放射性碘摄取(RAIU)正常。然而,根据更精细的标准,14例中只有6例似乎完全正常。1例患者血清促甲状腺激素(TSH)浓度显著升高,另外5例高于正常范围(1.6±2.0;均值±2标准差)。对11例接受检测的患者进行外源性TSH刺激甲状腺试验,发现7例患者血清T4、RAIU或两者的反应低于正常。10例患者中有5例碘-过氯酸盐释放试验异常,且在对TSH的RAIU反应异常的患者中异常最为明显。15例患者中有12例血清中发现荧光抗微粒体抗体,而同龄正常个体的预期出现频率为7%。到1978年完成第二项主要随访研究时,又有2例患者明显出现甲状腺功能减退。第3例受试者符合亚临床甲状腺功能减退的公认标准。其中1例在1972年血清TSH浓度明显升高,其余2例在1972年接受检测的10例患者中对促甲状腺激素释放激素的血清TSH反应最高(36、26 μU/ml)。1例患者在首次也是唯一一次明显的甲亢发作25年后,于1978年出现复发性甲状腺毒症。该患者是1972年对促甲状腺激素释放激素反应低于正常的唯一患者。其余9例在1978年能够接受研究的受试者表现出甲状腺功能异常的不同组合。结论是甲状腺功能进行性减退在长期格雷夫斯病中很常见,提示这是由伴发的慢性甲状腺炎导致的。我们推测这种甲状腺功能减退的内在倾向因手术或放射性碘而加剧,这解释了弥漫性毒性甲状腺肿采用消融治疗后甲状腺功能减退的逐渐增加及异常高的发生率。